pipette
ESEspañol

Uncertainty-aware longitudinal prediction of multiple adverse pregnancy outcomes

Y. Wu, S. Asvadi, M. van der Ven, E. Peri, M. Xu, M. B. van der Hout-van der Jagt, J. OEH van Laar, C. Chen, Q. Luo, M. Mischi, S. G. Oei, X. Long

PreprintReal-world use

In the authors' words

Risk of pregnancy complications is reassessed at each antenatal visit, but whether earlier predictions add information beyond the most recent one is unclear. Classifying every prediction as low or high risk can leave uncertainty unexpressed. Whether reliability per visit holds across visits is also unclear. This secondary analysis included 9289 nulliparous women from the nuMoM2b cohort (eight US centres, 2010-2013). Logistic regression models predicted gestational diabetes, pre-eclampsia, preterm birth, suspected fetal growth restriction and large for gestational age at 6-13, 16-21 and 22-29 weeks (Visits 3). Mondrian conformal prediction reported 'no' (low risk), 'yes' (high risk), or both (review). To test whether prediction history adds information beyond the Visit 3 prediction, we compared, among women classified as high risk at Visit 3, those first classified as high risk at Visit 2 or 3 (emerging high) with those classified as high risk at all three visits (persistent high), adjusting for Visit 3 predicted probability. The adjusted proportion with the outcome was higher in the emerging-high than the persistent-high group, by 6.1 percentage points for large for gestational age (95% CI -0.4 to 12.2) and 3.8 percentage points for suspected fetal growth restriction (-0.9 to 8.1). Other outcomes showed adjusted differences close to zero. With conformal prediction calibrated to a 90% level at each visit, the reported answers included the actual outcome in 89.6-90.6% of women at each visit (coverage). Coverage decreased when each woman's three visits were considered together (79.0-85.4%). For fetal growth outcomes, how a woman's predicted risk evolved during pregnancy may add information beyond her Visit 3 prediction. For repeated clinical use, the target coverage level should reflect the acceptable risk of incorrect low- or high-risk classifications over a woman's follow-up and the clinical decisions supported at each visit.

Main resultLimitation the authors admit

Appeared: Wednesday, November 18. medRxiv. Preprint, not yet peer-reviewed.

DOI: 10.64898/2026.11.15.26368140